Inhibition of cutaneous and mucosal allergy with phenyltoloxamine.
A dose-and-time related-effect of oral phenyltoloxamine citrate, a Class I, H1 antihistamine compound, has been demonstrated against allergen-induced wheal-and-erythema skin reactions among 10 adults with a diagnosis of allergic rhinitis and seasonal pollinosis. Clinical improvement in the existing symptoms of rhinorrhea, nasal obstruction, pruritus and sneezing, showed a significant correlation with the inhibition of reagin-mediated skin reactivity caused by phenytoloxamine. No adverse side effects were observed. It can be concluded that oral phenyltoloxamine citrate possesses antihistaminic properties and a range of safety which make it a useful agent for the symptomatic management of upper respiratory allergy.
D000293:Adolescent; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004983:Ethanolamines / Q000627:therapeutic use*; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009092:Mucous Membrane / Q000276:immunology; D006255:Rhinitis, Allergic, Seasonal / Q000517:prevention & control*; D012882:Skin Tests
D004983:Ethanolamines; D006634:Histamine H1 Antagonists